Abstract # 2251 Bulbo-Membranous Urethral Stricture - The Pathognomonic Late Toxicity Following High-Dose-Rate Brachytherapy For Prostate Cancer?

Presenter: Sullivan, Lisa

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

Data from 474 patients with clinically localised prostate cancer treated with HDRB between September 1997 and September 2005 were analysed. Ninety percent of patients received HDRB as a boost to external beam radiotherapy (HDRBB) and 10% received HDRB as monotherapy (HDRBM), using single implants. The first 108 patients receiving HDRBB and the 47 HDRBM patients were enrolled on prospective trials, and all patients without active follow-up at our institution had their treating physicians directly contacted. Concurrent hormonal therapy was used in 41%. Urethral strictures were diagnosed following investigation of urinary tract symptoms and were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.